BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS $0.22 Up 69%; Cash and Short-Term Investments $8.0 Million Up 82%

TORONTO, ONTARIO-- (Feb 25, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Fiscal 2014 and Fourth Quarter (Q4 2014) financial results. Key highlights include:

• Full Year 2014 Sales of $12,211,127 increased by 57% versus 2013
• Revenue has grown at a compound annual growth rate (CAGR) of 63% over the last 3 years
• Full Year 2014 Pharmaceutical Sales of $11,331,269 up 63% versus 2013
• Fourth quarter sales increased by 43% from $2,142,835 in Q4 2013 to $3,058,503 in Q4 2014

• Full Year 2014 EBITDA¹ of $4,299,963 increased by 73% versus 2013
• Q4 2014 EBITDA¹ of $1,056,576 increased by 72% over Q4 2013
• 2014 Net Income Before Tax of $4,326,735 increased by 76% versus 2013
• Net Income Before Tax for Q4 2014 of $1,068,563, was 73% higher than $619,124 in Q4 2013
• 2014 Net Income After Tax of $3,154,079 increased by 64% versus 2013
• Q4 2014 Net Income After Tax of $753,199 increased by 74% over Q4 2013, excluding one-time recognition of deferred tax credit of $123,332 in Q4 2013
• 2014 Fully Diluted EPS of $0.22 increased by 69%versus $0.13 in 2013
• Cash Generation in 2014 of $3,608,003 was 75% higher than 2013
• Cash & Short Term Investments of $7,989,140 as at December 31, 2014 increased by 82% over 2013
• The Company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada
• In 2014, BioSyent was named as one of Canada's fastest growing companies in the Profit 500 rankings with a five year growth rate of 608%

Total sales for Q4 2014 of $3,058,503, were 43% higher compared to $2,142,835 in the corresponding prior year period. On a full year basis, sales in 2014 of $12,211,127 were 57% higher than the previous year sales of $7,799,426.

Net Income Before Tax for Q4 2014 of $1,068,563, was 73% higher than $619,124 in Q4 2013. Net Income Before Tax for full year 2014 was $4,326,735 or 76% higher than the corresponding prior year period.

Q4 2014 Net Income After Tax of $753,199 increased by 74% over Q4 2013, excluding one-time recognition of deferred tax credit of $123,332 in Q4 2013. Net Income After Tax for full year 2014 was $3,154,079 or 64% higher than $1,928,028 in 2013.

Cash & Short Term Investments of $7,989,140 as at December 31, 2014 increased by 82% over 2013. Working capital, which is the difference between current assets and current liabilities, increased by 77% from $4,405,910 as at December 31, 2013 to $7,786,460 as at December 31, 2014.

Total Shareholder's Equity increased by 68% from $4,854,630 at December 31, 2013 to $8,160,092 at December 31, 2014.

"2014 marked our fifth consecutive year of greater than 50% top-line growth" commented René Goehrum, President and CEO of BioSyent. "With four launch phase products and two in growth phase, we have set the stage for continued progress in 2015 and 2016. This includes three product launches in the last nine months. In addition, we have more new product opportunities in our negotiation funnel than we have ever had before."

The Company's Consolidated Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on February 25, 2015.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

BioSyent will also release a CEO presentation on the Fourth Quarter at the following link www.biosyent.com/q4-14/

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,851,195 shares issued and outstanding.

¹EBITDA - is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards ("IFRS") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.